EPO grants eukaryotic cell CRISPR patent to Charpentier
The European Patent Office (EPO) has issued a new CRISPR/Cas9 patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Today, April 3, ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Charpentier, announced she had been granted European patent number 3,401,400.
The patent claims methods and compositions of using CRISPR/Cas9 to modify DNA and regulate gene activity in eukaryotic cells, including kits to carry out such work.
Eric Rhodes, CEO of ERS Genomics said welcomed the addition of the patent to its portfolio.
“The most common use for CRISPR/Cas9 is in eukaryotic cells, including human and animal cells,” Rhodes said.
“We are pleased to have another comprehensive patent covering methods, compositions and kits for such uses which adds to our portfolio of patents which have issued in over 40 countries worldwide,” he said.
The news comes shortly after the US Patent and Trademark Office issued a third CRISPR patent to Charpentier in March.
Filed in November 2015, the patent specifically includes uses of single guide RNA formats of the CRISPR/Cas9 technology ‘in a cell’. In a cell specifically includes any cell type, including animal, plant and human cells.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk